Ipsen signs $1.8bn RNA drug alliance with Skyhawk
Ipsen has expanded its R&D pipeline once again, agreeing a $1.8 billion alliance with Skyhawk Therapeutics focused on the development of RNA-targeting therapies for rare neurological diseases. The deal – which covers development, regulatory, and …